Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 28 July 2006
Potential for treatment of spinal
muscular atrophy
Oxford Biomedica publishes 'promising' preclinical efficacy results with its product candidate smn1-g for spinal muscular atrophy
Oxford BioMedica announces the publication of promising preclinical results with its product candidate, SMN1-G, for the treatment of spinal muscular atrophy (SMA), in the Journal of Clinical Investigation SMA is a fatal genetic disease that affects the spinal cord and brain stem
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
Avian transgenic breakthrough reported
Results are first proof-of-principle with an avian-expressed version of interferon beta; it is expected that the Ova system will be capable of cost-effectively expressing many therapeutic proteins
To date there are no effective drug treatments for SMA.
The preclinical results published in the Journal of Clinical Investigation (Volume: 114, No: 12, pp: 1726-1731), suggest that SMN1-G may have potential in the treatment of this genetic disease.
The preclinical studies were supported by FightSMA, a US charitable organisation.
In these studies, mice with a defective SMN gene were given intramuscular injections with either SMN1-G or a control.
The mice treated with SMN1-G showed a statistically significant improvement in survival together with improved motor neuron survival.
SMA is one of the most common genetic diseases leading to death in childhood.
The disease, characterised by degeneration of motor neurons in the spinal cord and brain stem leading to muscle weakness, is caused by mutations or deletion of the SMN1 gene.
SMN1-G is Oxford BioMedica's gene-based therapeutic which utilises the company's LentiVector gene delivery system carrying a corrected SMN1 gene.
The company anticipates progressing SMN1-G into clinical development during 2006.
Martha Slay, president of FightSMA, said, "For the first time ever, researchers have replaced a missing gene in a mouse model of SMA, a disease that kills more infants than any other genetic disorder." Oxford BioMedica's CEO, professor Alan Kingsman, said, "We are very encouraged by our preclinical data with SMN1-G and its potential to reverse the effects of this fatal disease".
"We believe that there is a significant commercial opportunity in the development of a safe and effective treatment for this unmet medical need.".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
